SHP Share PerformanceMore
|52 week high||5,377.0 20/09/16|
|52 week low||2,707.0 13/07/16|
|52 week change||470.5 (11.62%)|
|4 week volume||49,650,913 29/05/17|
Latest News« previous» nextMore
22/06/2017 - 12:54 RNS
Director Declaration June 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the ?Company?) announces that Flemming Ornskov, MD, MPH, Chief Executive Officer of the Company, was appointed to the Board of Directors of Waters Corporation on June 22, 2017. This notification is to satisfy the Company?s obligations under LR 9.6.14R of the UK Listing Rules. Stephe...
22/06/2017 - 10:10 StockMarketWire
Citigroup today reaffirms its buy investment rating on Shire PLC (LON:SHP) and set its price target at 6500p.
21/06/2017 - 16:50 StockMarketWire
Sterling bounced back from earlier weakness as the Queen's Speech suggested there may be a softer tone on Brexit. UK Pri...
21/06/2017 - 11:45 StockMarketWire
The FTSE 100 was trading 0.3% lower as the market looked ahead to the Queen's Speech, which was expected to include new...
21/06/2017 - 08:53 StockMarketWire
The FTSE began lower with sterling falling notably against the dollar and euro as the market awaits the Queen's Speech lat...
21/06/2017 - 07:23 StockMarketWire
Shire said the US FDA has approved Mydayis, a once-daily treatment comprised of three different types of drug-releasing ...
21/06/2017 - 07:00 RNS
U.S. FDA Approves Mydayis TM (mixed salts of a single-entity amphetamine product) ? A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measur...
13/06/2017 - 08:30 StockMarketWire
Deutsche Bank today reaffirms its buy investment rating on Shire PLC (LON:SHP) and cut its price target to 6000p (from...
Latest discussion posts More
“Rhigos = sentiment is certainly under pressure, with quite a big sell day today, and I really dont know if the Trump is still causing uncertainty (alas he is BAD NEWS!) but ...”▼
“Shire has announced positive topline Phase 3 results for the HELP study that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 ...”▼
Codes & Symbols
|Symbols||SHP, LSE:SHP, SHP.L, SHP:LN, LON:SHP, XLON:SHP|